ScholarLens Back to search
2022•JAAD Case ReportsOpen access

A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib

Jiahui Zhao, Lingling Liu

Open full text 24 citations

Abstract

Atopic dermatitis (AD) is sometimes accompanied by alopecia areata (AA) or, in severe cases, alopecia universalis (AU). Preclinical studies have shown that type 1 and type 2 cytokines are involved in AD and AA.1,2 Janus kinase (JAK) inhibitors are effective blockers of JAK/signal transducer and activator of transcription-mediated inflammatory signaling pathways, which regulate multiple cytokines, such as interleukins and interferons.3 A recent case report showed hair regrowth after simultaneous treatment of AU and AD with tofacitinib, a selective inhibitor of JAK 1 and JAK 3.

Open-access reader

About this research paper

What this paper is about

Atopic dermatitis (AD) is sometimes accompanied by alopecia areata (AA) or, in severe cases, alopecia universalis (AU). Preclinical studies have shown that type 1 and type 2 cytokines are involved in AD and AA.1,2 Janus kinase (JAK) inhibitors are effective blockers of JAK/signal transducer and activator of transcription-mediated inflammatory signaling pathways, which regulate multiple cytokines, such as interleukins and interferons.3 A recent case report showed hair regrowth after simultaneous treatment of AU and AD with tofacitinib, a selective inhibitor of JAK 1 and JAK 3.

Why it matters

OpenAlex reports 24 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Atopic dermatitis (AD) is sometimes accompanied by alopecia areata (AA) or, in severe cases, alopecia universalis (AU). Preclinical studies have shown that type 1 and type 2 cytokines are involved in AD and AA.1,2 Janus kinase (JAK) inhibitors are effective blockers of JAK/signal transducer and activator of transcription-mediated inflammatory signaling pathways, which regulate multiple cytokines, such as interleukins and interferons.3 A recent case report showed hair regrowth after simultaneous treatment of AU and AD with tofacitinib, a selective inhibitor of JAK 1 and JAK 3.

Key concepts: Tofacitinib, Janus kinase, Alopecia areata, Medicine, Alopecia universalis, Atopic dermatitis, STAT protein, Janus kinase 1

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
A case of atopic dermatitis with alopecia universalis in a patient treated with abrocitinib — Research Paper | ScholarLens